MPN Education and Newsletters
Besides pursuing with the clinical development of new treatments, an important goal of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms (MPNs) is to educate physicians, patients and their families, and the community about novel, promising MPN medications and the latest clinical research findings.
We periodically publish the patient-centered newsletter MPN Focus (current and past issues are available in the panel below) where we present all the active clinical trials evaluating emerging MPN medications in clinical development at MD Anderson and highlight the most important findings from MPN clinical research studies. These studies are presented at the national and international hematology/oncology conferences, such as the American Society of Hematology, the American Society for Clinical Oncology, the Society of Hematologic Oncology, and the European Hematology Association.
Furthermore, we frequently engage in educational symposia and conferences for physicians and patients; for example, from 2013 to 2017, we organized and hosted five annual MPN Patient Meetings at MD Anderson, in collaboration with the patient support groups (photo to the left, 2013 Meeting). Other educational activities that the MPN Team engages in include video presentations on novel MPN treatments at online forums, such as Patient Power, PV Reporter, and others; and invited presentations at the annual meetings of ASH, EHA, SOHO, ASCO, the Texas MPN Workshops, and many others.
LEARN MORE: Professor Verstovsek presented 19 educational videos on Myeloproliferative Neoplasms (myelofibrosis, polycythemia vera and essential thrombocytemia) for patients
LEARN MORE: Professor Verstovsek presented the comprehensive educational podcast "A Deep Dive into Myelofibrosis"
LEARN MORE: Professor Verstovsek presented several educational interviews for patients/caregivers on the latest MPN treatments at "The Patient Story":
- Novel Treatments in Development for Myelofibrosis
- Novel Treatments in Development for Polycythemia Vera
- Novel Treatment for Myeloid Lymphoid Neoplasms (MLN)
This is a very exciting time because many new medications are being developed to treat MPNs.
Srdan Verstovsek, M.D., Ph.D.
Professor of Medicine; Director of the Hanns A. Pielenz Clinical Research Center for MPN
Issues
-
ISSUE 17: SPRING 2022
-
ISSUE 16: WINTER 2021-22
-
ISSUE 15: SUMMER 2021
-
ISSUE 14: WINTER 2020-21
-
ISSUE 13: SUMMER 2020
-
Issue 12: Winter 2020
-
Issue 11: Winter 2019
-
Issue 10: Spring 2018
-
Issue 9: Fall 2017
-
Issue 8: Winter 2017
-
Issue 7: Fall 2016
-
Issue 6: Spring 2016
-
Issue 5: Fall 2015
-
Issue 4: Spring 2015
-
Issue 3: Fall 2014
-
Issue 2: Spring 2014
-
Issue 1: Fall 2013
Letter from the Director of Clinical Research Center for MPN
Overview of Myeloproliferative Neoplasms